In summary, the present study indicates that the gender difference is involved in the development of esophageal cancer, and estradiol treatment increases the expression of GRP78, ATF6, IRE1, and PERK through estrogen receptor, and upregulates ERS to inhibit the viability and migration of esophageal cancer cells (Figure 6). Here, ATF6 is linked to esophageal cancer.